Skip to content

Occludin and Zonulin in Attention-deficit/Hyperactivity Disorder

Serum Occludin and Zonulin Levels in Attention-deficit/Hyperactivity Disorder

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05502471
Enrollment
79
Registered
2022-08-16
Start date
2021-01-01
Completion date
2021-06-01
Last updated
2022-08-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Attention-deficit/Hyperactivity Disorder

Brief summary

The association between levels of zonulin and occludin and behavioral/emotional problems in children with ADHD are investigated.

Detailed description

Inclusion criteria for the ADHD group are (a) newly diagnosed ADHD (b) no prior psychotropic treatment for ADHD or any psychiatric disorder (c) age 6-12 years. Exclusion criteria were: (a) history of history of inflammatory/noninflammatory, metabolic, or autoimmune disease (b) any special diet history within the past year (c) use of corticosteroids or regular intake of medication in the last 6 months, (d) body mass index (BMI) \[kg/m2\] \> 30), and (e) cognitive deficits by developmental history.

Interventions

DIAGNOSTIC_TESTZonulin

Serum zonulin level

DIAGNOSTIC_TESTOccludin

Serum occludin level

Sponsors

Ataturk University
Lead SponsorOTHER

Study design

Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
DIAGNOSTIC
Masking
SINGLE (Investigator)

Eligibility

Sex/Gender
ALL
Age
6 Years to 12 Years
Healthy volunteers
Yes

Inclusion criteria

* (a) newly diagnosed ADHD * (b) no prior psychotropic treatment for ADHD or any psychiatric disorder * (c) age 6-12 years.

Exclusion criteria

* (a) history of history of inflammatory/noninflammatory, metabolic, or autoimmune disease * (b) any special diet history within the past year * (c) use of corticosteroids or regular intake of medication in the last 6 months, * (d) body mass index (BMI) \[kg/m2\] \> 30), * (e) cognitive deficits by developmental history

Design outcomes

Primary

MeasureTime frameDescription
Zonulin level1 monthSerum Zonulin level after psychiatric interview
Occludin level1 monthSerum Occludin level after psychiatric interview

Countries

Turkey (Türkiye)

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026